A view from the Center

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

Unlocking the untapped potential of intelligent automation in life sciences

by Shirish Gupta, senior manager, and Muna Tuna, senior manager, Deloitte Consulting LLP

Intelligent Automation (IA)—the combination of artificial intelligence and automation—is rapidly becoming mainstream in nearly every sector of our economy. Companies are using IA to improve operational efficiencies by performing repetitive tasks far more quickly and accurately. Beyond improvements in productivity, IA also can enable higher levels of business value through innovation and strategic growth.

While industries such as financial services and retail have tapped into the potential of IA,

Read more

Demonstrating and rewarding value in health care

by Jeff Morgan, Managing Director, Deloitte Consulting LLP

The growing importance of real world evidence and value-based contracting programs

As the cost of health care continues to rise, life sciences companies are facing mounting pricing pressure and a growing need to continuously demonstrate the value of their products in a real-world population. These market forces are driving more and more life sciences companies to invest in new capabilities with the goal of harnessing the power of real world data (RWD) and changing how value is both demonstrated and rewarded.

Read more

Moving value-based contracting from experimentation to common practice

by Jeff Morgan, Managing Director, Deloitte Consulting LLP

As the health care world continues its shift from volume- to value-based reimbursement, value-based contracts (VBC) between life sciences companies and payers that tie the reimbursement of a product to the value it delivers are gaining traction.

The health care system is going through a volume-to-value transformation with the goal of controlling cost and improving patient outcomes.

Read more

CMS’s latest step to reduce MA drug costs goes into effect on January 1

by Akhil Rao, manager, and Michael Cohen, specialist leader, Deloitte Consulting LLP

Beginning on January 1, CMS will allow Medicare Advantage (MA) plans to use step therapy for physician-administered drugs prescribed under Medicare Part B. Step therapy may help reduce drug spending for MA plans and beneficiaries by requiring patients to try less-costly Part D therapies before moving on to more expensive injected or infused drugs.

Reducing drug prices has been a top priority for the administration,

Read more

Life sciences outlook for 2019: Moving from the hypothetical into a new reality

by Greg Reh, Vice Chairman, US and Global Life Sciences Leader, Deloitte LLP

As we step into the new year, the pace of change in life sciences feels like it is moving faster than ever. While trends in the industry generally take place over decades rather than years, many of the foundational elements to shift from treatment to wellness, for example, are beginning to take shape.

Several trends will likely continue to shape biopharmaceutical and medical device manufacturers in 2019.

Read more

The potential of immuno-oncology could lead biopharma companies to rethink growth strategies

by Susan Dettmar, principal, US M&A consultative services leader, and Kushan Biswas, Life Sciences M&A senior manager, Deloitte Consulting LLP

A new era in the treatment of cancer is helping fuel a strategy shift among biopharmaceutical manufacturers that want to take advantage of a rapidly evolving market. The potential of immuno-oncology—which leverages the immune system to treat various forms of cancer—has prompted some biopharmaceutical companies to move investments from other areas of research. Immuno-oncology is expected to grow 142 percent1—from $14 billion in 2019 to $34 billion in 2024.

Read more